These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Depatuxizumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFR von Achenbach C; Silginer M; Blot V; Weiss WA; Weller M Mol Cancer Ther; 2020 Jun; 19(6):1328-1339. PubMed ID: 32371586 [TBL] [Abstract][Full Text] [Related]
6. An Integrated Population Pharmacokinetic Model Versus Individual Models of Depatuxizumab Mafodotin, an Anti-EGFR Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Overexpress EGFR. Mittapalli RK; Stodtmann S; Friedel A; Menon RM; Bain E; Mensing S; Xiong H J Clin Pharmacol; 2019 Sep; 59(9):1225-1235. PubMed ID: 30990907 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor. Goss GD; Vokes EE; Gordon MS; Gandhi L; Papadopoulos KP; Rasco DW; Fischer JS; Chu KL; Ames WW; Mittapalli RK; Lee HJ; Zeng J; Roberts-Rapp LA; Loberg LI; Ansell PJ; Reilly EB; Ocampo CJ; Holen KD; Tolcher AW Cancer; 2018 May; 124(10):2174-2183. PubMed ID: 29533458 [TBL] [Abstract][Full Text] [Related]
8. Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR. Vaidya KS; Mitten MJ; Zelaya-Lazo AL; Oleksijew A; Alvey C; Falls HD; Mishra S; Palma J; Ansell P; Phillips AC; Reilly EB; Anderson M; Boghaert ER J Neurooncol; 2021 Apr; 152(2):233-243. PubMed ID: 33517558 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. van den Bent M; Gan HK; Lassman AB; Kumthekar P; Merrell R; Butowski N; Lwin Z; Mikkelsen T; Nabors LB; Papadopoulos KP; Penas-Prado M; Simes J; Wheeler H; Walbert T; Scott AM; Gomez E; Lee HJ; Roberts-Rapp L; Xiong H; Bain E; Ansell PJ; Holen KD; Maag D; Reardon DA Cancer Chemother Pharmacol; 2017 Dec; 80(6):1209-1217. PubMed ID: 29075855 [TBL] [Abstract][Full Text] [Related]
10. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies. Hu XY; Wang R; Jin J; Liu XJ; Cui AL; Sun LQ; Li YP; Li Y; Wang YC; Zhen YS; Miao QF; Li ZR Mol Oncol; 2019 Feb; 13(2):246-263. PubMed ID: 30372581 [TBL] [Abstract][Full Text] [Related]
11. Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma. Marin BM; Porath KA; Jain S; Kim M; Conage-Pough JE; Oh JH; Miller CL; Talele S; Kitange GJ; Tian S; Burgenske DM; Mladek AC; Gupta SK; Decker PA; McMinn MH; Stopka SA; Regan MS; He L; Carlson BL; Bakken K; Burns TC; Parney IF; Giannini C; Agar NYR; Eckel-Passow JE; Cochran JR; Elmquist WF; Vaubel RA; White FM; Sarkaria JN Neuro Oncol; 2021 Dec; 23(12):2042-2053. PubMed ID: 34050676 [TBL] [Abstract][Full Text] [Related]
13. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Van Den Bent M; Eoli M; Sepulveda JM; Smits M; Walenkamp A; Frenel JS; Franceschi E; Clement PM; Chinot O; De Vos F; Whenham N; Sanghera P; Weller M; Dubbink HJ; French P; Looman J; Dey J; Krause S; Ansell P; Nuyens S; Spruyt M; Brilhante J; Coens C; Gorlia T; Golfinopoulos V Neuro Oncol; 2020 May; 22(5):684-693. PubMed ID: 31747009 [TBL] [Abstract][Full Text] [Related]
14. Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. Lassman AB; Pugh SL; Wang TJC; Aldape K; Gan HK; Preusser M; Vogelbaum MA; Sulman EP; Won M; Zhang P; Moazami G; Macsai MS; Gilbert MR; Bain EE; Blot V; Ansell PJ; Samanta S; Kundu MG; Armstrong TS; Wefel JS; Seidel C; de Vos FY; Hsu S; Cardona AF; Lombardi G; Bentsion D; Peterson RA; Gedye C; Bourg V; Wick A; Curran WJ; Mehta MP Neuro Oncol; 2023 Feb; 25(2):339-350. PubMed ID: 35849035 [TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. Lassman AB; van den Bent MJ; Gan HK; Reardon DA; Kumthekar P; Butowski N; Lwin Z; Mikkelsen T; Nabors LB; Papadopoulos KP; Penas-Prado M; Simes J; Wheeler H; Walbert T; Scott AM; Gomez E; Lee HJ; Roberts-Rapp L; Xiong H; Ansell PJ; Bain E; Holen KD; Maag D; Merrell R Neuro Oncol; 2019 Jan; 21(1):106-114. PubMed ID: 29982805 [TBL] [Abstract][Full Text] [Related]
16. Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma. Clement PMJ; Dirven L; Eoli M; Sepulveda-Sanchez JM; Walenkamp AME; Frenel JS; Franceschi E; Weller M; Chinot O; De Vos FYFL; Whenham N; Sanghera P; Looman J; Kundu MG; Peter de Geus J; Nuyens S; Spruyt M; Gorlia T; Coens C; Golfinopoulos V; Reijneveld JC; van den Bent MJ Eur J Cancer; 2021 Apr; 147():1-12. PubMed ID: 33601293 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of depatuxizumab mafodotin (ABT-414) in preclinical models of head and neck cancer. Mani L; Naveed A; McAdoo A; Rosenthal E; Hom M Carcinogenesis; 2024 Jul; 45(7):520-526. PubMed ID: 38375733 [TBL] [Abstract][Full Text] [Related]
18. Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy. Li Z; Wang M; Yao X; Luo W; Qu Y; Yu D; Li X; Fang J; Huang C Target Oncol; 2019 Feb; 14(1):93-105. PubMed ID: 30635821 [TBL] [Abstract][Full Text] [Related]
19. Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer. Li Z; Wang M; Yu D; Luo W; Fang J; Huang C; Yao X Cancer Chemother Pharmacol; 2019 Jul; 84(1):61-72. PubMed ID: 31037333 [TBL] [Abstract][Full Text] [Related]
20. Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer. Zoeller JJ; Vagodny A; Daniels VW; Taneja K; Tan BY; DeRose YS; Fujita M; Welm AL; Letai A; Leverson JD; Blot V; Bronson RT; Dillon DA; Brugge JS Breast Cancer Res; 2020 Nov; 22(1):132. PubMed ID: 33256808 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]